Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
Latest Information Update: 02 Jan 2025
Price :
$35 *
At a glance
- Drugs Dostarlimab (Primary) ; Niraparib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRIME
- 17 Mar 2021 Status changed from not yet recruiting to recruiting.
- 04 Jan 2021 Planned initiation date changed from 20 Dec 2020 to 1 Feb 2021.
- 29 Dec 2020 New trial record